PriceTargets.com logo

4D Molecular Therapeutics - FDMT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $42.56
  • Forecasted Upside: 574.41%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$6.31 As of 12/20/2024 06:31 PM ET
▲ +0.53 (9.17%)

This chart shows the closing price for FDMT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New 4D Molecular Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FDMT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FDMT

Analyst Price Target is $42.56
▲ +574.41% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for 4D Molecular Therapeutics in the last 3 months. The average price target is $42.56, with a high forecast of $81.00 and a low forecast of $8.00. The average price target represents a 574.41% upside from the last price of $6.31.

This chart shows the closing price for FDMT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 contributing investment analysts is to moderate buy stock in 4D Molecular Therapeutics. This rating has held steady since September 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/18/2024Bank of AmericaLower TargetBuy ➝ Buy$79.00 ➝ $46.00
11/21/2024Morgan StanleyInitiated CoverageUnderweight$8.00
11/14/2024Chardan CapitalReiterated RatingBuy ➝ Buy$39.00 ➝ $39.00
11/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
11/14/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$40.00 ➝ $39.00
9/23/2024Cantor FitzgeraldDowngradeOverweight ➝ Neutral
9/19/2024Chardan CapitalBoost TargetBuy ➝ Buy$38.00 ➝ $39.00
9/19/2024Leerink PartnersReiterated RatingOutperform ➝ Outperform$40.00 ➝ $36.00
9/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
8/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
7/22/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00
7/18/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$63.00 ➝ $40.00
7/17/2024Chardan CapitalReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
6/26/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00
6/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00
4/15/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$35.00 ➝ $40.00
4/15/2024BarclaysInitiated CoverageOverweight
4/1/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$70.00 ➝ $63.00
4/1/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$30.00 ➝ $58.00
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00
2/7/2024The Goldman Sachs GroupReiterated RatingBuy$81.00
2/5/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$50.00 ➝ $70.00
2/5/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$25.00 ➝ $35.00
1/29/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$25.00
10/26/2023Royal Bank of CanadaInitiated CoverageOutperform$25.00
10/24/2023Cantor FitzgeraldInitiated CoverageOverweight$32.00
10/18/2023Leerink PartnrsUpgradeMarket Perform ➝ Outperform
10/18/2023Leerink PartnersUpgradeMarket Perform ➝ Outperform$24.00
8/11/2023Chardan CapitalReiterated RatingBuy ➝ Buy$31.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$36.00
7/31/2023HC WainwrightReiterated RatingBuy ➝ Buy$36.00
7/11/2023Chardan CapitalBoost Target$30.00 ➝ $31.00
7/5/2023Chardan CapitalInitiated CoverageBuy$30.00
6/8/2023Bank of AmericaBoost Target$28.00 ➝ $33.00
4/13/2023SVB SecuritiesLower TargetMarket Perform$14.00 ➝ $13.00
3/16/2023HC WainwrightReiterated RatingBuy$36.00
2/23/2023HC WainwrightReiterated RatingBuy$36.00
2/6/2023Leerink PartnersLower TargetMarket Perform$15.00 ➝ $14.00
2/6/2023HC WainwrightReiterated RatingBuy$36.00
1/30/2023BMO Capital MarketsInitiated CoverageOutperform$50.00
11/18/2022HC WainwrightInitiated CoverageBuy$36.00
11/15/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$12.00 ➝ $68.00
11/14/2022Bank of AmericaBoost Target$15.00 ➝ $25.00
11/14/2022Evercore ISIBoost Target$32.00 ➝ $45.00
11/10/2022Leerink PartnersBoost TargetMarket Perform$10.00 ➝ $11.00
8/12/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$28.00 ➝ $12.00
6/22/2022Jefferies Financial GroupInitiated CoverageBuy$22.00
1/4/2022Leerink PartnersInitiated CoverageOutperform$30.00
1/5/2021Evercore ISIInitiated CoverageOutperform
1/5/2021Bank of AmericaInitiated CoverageBuy$47.00
1/5/2021The Goldman Sachs GroupInitiated CoverageNeutral$44.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
5/25/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 11 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 8 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 5 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 6 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 6 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

4D Molecular Therapeutics logo
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $6.31
Low: $5.74
High: $6.37

50 Day Range

MA: $7.79
Low: $5.78
High: $9.03

52 Week Range

Now: $6.31
Low: $5.58
High: $36.25

Volume

4,762,978 shs

Average Volume

907,024 shs

Market Capitalization

$291.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.74

Frequently Asked Questions

What sell-side analysts currently cover shares of 4D Molecular Therapeutics?

The following Wall Street research analysts have issued research reports on 4D Molecular Therapeutics in the last twelve months: Bank of America Co., Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Chardan Capital, HC Wainwright, Jefferies Financial Group Inc., Leerink Partners, Morgan Stanley, Royal Bank of Canada, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for FDMT.

What is the current price target for 4D Molecular Therapeutics?

0 Wall Street analysts have set twelve-month price targets for 4D Molecular Therapeutics in the last year. Their average twelve-month price target is $42.56, suggesting a possible upside of 574.4%. The Goldman Sachs Group, Inc. has the highest price target set, predicting FDMT will reach $81.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $8.00 for 4D Molecular Therapeutics in the next year.
View the latest price targets for FDMT.

What is the current consensus analyst rating for 4D Molecular Therapeutics?

4D Molecular Therapeutics currently has 1 sell rating, 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for FDMT.

What other companies compete with 4D Molecular Therapeutics?

Other companies that are similar to 4D Molecular Therapeutics include Calliditas Therapeutics AB (publ), ARS Pharmaceuticals, Syndax Pharmaceuticals, ANI Pharmaceuticals and Rocket Pharmaceuticals. Learn More about companies similar to 4D Molecular Therapeutics.

How do I contact 4D Molecular Therapeutics' investor relations team?

The company's listed phone number is 510-505-2680 and its investor relations email address is [email protected]. The official website for 4D Molecular Therapeutics is www.4dmoleculartherapeutics.com. Learn More about contacing 4D Molecular Therapeutics investor relations.